 This study is predicated on the continued development of agents targeting the PI3K pathway such as AZDAstraZeneca Drug8186 PI3Kb; AZD5363 Akt and AZD2014 mTOR and anti-hormonals which are expected to deliver benefit in the management of tumours dependent on PI3K signalling as a result of e.g. phosphatase and tensin homolog PTEN deficiency or androgen receptor activation. 